alprazolam
Approved
Oct 16, 1981
Alprazolam, a benzodiazepine, is used to treat panic disorder and anxiety disorder. Unlike chlordiazepoxide, clorazepate, and prazepam, alprazolam has a shorter half-life and metabolites with minimal activity. Alprazolam may have significant drug interactions involving the hepatic cytochrome P-450 3A4 isoenzyme. Clinically, all benzodiazepines cause a dose-related central nervous system depressant activity varying from mild impairment of task performance to hypnosis. Unlike other benzodiazepines, alprazolam may also have some antidepressant activity, although clinical evidence of this is lacking. CNS agents of the 1,4 benzodiazepine class presumably exert their effects by binding at stereo specific receptors at several sites within the central nervous system. Their exact mechanism of action is unknown. Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. — NCATS
Clinical trial activity
104 trials · 92 clinical orgs · 31 marketing orgs
Earliest trial started Nov 1, 1991 (NCT00913341)
Timeline
1980s
- Oct 16, 1981
Upjohn — Earliest FDA Approval
- Oct 16, 1981
Pharmacia & Upjohn — NDA Secondary Org
- Oct 16, 1981
Upjohn — Marketing Organization
- Oct 16, 1981
Upjohn — NDA Organization
1990s
- Jan 1, 1991
- May 27, 1993
Roxane Laboratories — Marketing Organization
- May 27, 1993
Boehringer Ingelheim — Marketing Organization
- Oct 19, 1993
DAVA Pharmaceuticals — Marketing Organization
- Oct 19, 1993
Novitium Pharma — Marketing Organization
- Oct 31, 1993
Actavis — Marketing Organization
- Oct 31, 1993
West-Ward Pharmaceutical — Marketing Organization
- Oct 31, 1993
Hikma — Marketing Organization
- Jan 27, 1994
Mylan — Marketing Organization
- Feb 16, 1994
Ani Pharmaceuticals — Marketing Organization
- Jul 29, 1994
Teva — Marketing Organization
- Aug 31, 1995
Watson Pharmaceuticals — Marketing Organization
- Dec 29, 1995
Sandoz — Marketing Organization
- Jan 1, 1997
Earliest Phase 2 Sponsor(trial)
- Mar 25, 1998
Novartis — Marketing Organization
2000s
- Jan 17, 2003
Pharmacia — NDA Secondary Org
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
- Jan 19, 2005
UCB — NDA Secondary Org
- Jan 19, 2007
Apotex — Marketing Organization
- May 24, 2007
Impax Laboratories — Marketing Organization
- Oct 15, 2007
Vintage — Marketing Organization
- Oct 15, 2007
Apax Partners — Marketing Organization
- May 30, 2008
Amneal Pharmaceuticals — Marketing Organization
- Sep 25, 2008
Oxford Pharmaceuticals — Marketing Organization
- Oct 17, 2008
Heritage Pharma — Marketing Organization
- Jan 9, 2009
Par Pharmaceuticals — Marketing Organization
2010s
- Jun 17, 2010
Sun Pharmaceuticals — Marketing Organization
- Sep 17, 2010
Strides Pharma Science — Marketing Organization
- Jun 7, 2011
Aurobindo Pharma — Marketing Organization
- Sep 29, 2011
Anchen Pharmaceuticals, Inc — Marketing Organization
- Apr 15, 2015
Natco Pharma — Marketing Organization
- Jul 9, 2018
Esteve Labs — Marketing Organization
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 1/Phase 2
- Acute Disease · Phase 4
- Alcohol Withdrawal Delirium · Phase 4
- Alzheimer Disease · Phase 1
- Anesthesia and Analgesia · Phase 4
- Anxiety Disorders · Phase 4
- Asthma · Phase 1
- Automobile Driving · Phase 4
- Cannabis · Phase 1
- Cognition Disorders · Phase 4
- Delirium · Phase 4
- Dementia · Phase 3
- Dental Anxiety · Phase 2
- Depression · Phase 3
- Diabetes Mellitus, Type 1 · Phase 1/Phase 2
- Disability Evaluation · Phase 2
- Driving Under the Influence · Phase 1
- Drug Interactions · Phase 1/Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 4
- Epilepsy · Phase 2
- Food-Drug Interactions · Phase 1
- General Surgery · Phase 4
- Genital Diseases, Female · Phase 4
- Geriatrics · Phase 4
- Healthy Volunteers · Phase 4
- Heart Diseases · Phase 1/Phase 2
- Huntington Disease · Phase 1
- Liver Diseases · Phase 1
- Migraine Disorders · Phase 1
- Myocardial Infarction · Phase 1/Phase 2
- Opioid-Related Disorders · Phase 2
- Pain · Phase 2
- Paresis · Phase 2
- Perioperative Care · Phase 4
- Pharmacokinetics · Phase 1/Phase 2
- Phobia, Social · Phase 1
- Postoperative Cognitive Complications · Phase 4
- Procedural Sedation · Phase 4
- Psychomotor Agitation · Phase 4
- Psychomotor Disorders · Phase 4
- Psychophysiologic Disorders · Phase 3
- Recreational Drug Use · Phase 1
- Schizophrenia · Phase 3
- Seizures · Phase 3
- Sleep Wake Disorders · Phase 4
- ST Elevation Myocardial Infarction · Phase 1/Phase 2
- Stomach Diseases · Phase 2/Phase 3
- Stress Disorders, Post-Traumatic · Phase 2/Phase 3
- Substance Abuse, Oral · Phase 4
- Urinary Bladder Neoplasms · Phase 4
Mechanism of action
- GABA-A receptor; anion channelPOSITIVE ALLOSTERIC MODULATOR
GABA-A receptor; anion channel positive allosteric modulator
Benzodiazepine site
- Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) ↗
- Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) ↗
- Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) ↗
- Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) ↗
- Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4) ↗
- Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) ↗
- Gamma-aminobutyric acid receptor subunit theta (GABRQ) ↗
- Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3) ↗
- Gamma-aminobutyric acid receptor subunit pi (GABRP) ↗
- Gamma-aminobutyric acid receptor subunit delta (GABRD) ↗
- Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) ↗
- Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) ↗
- Gamma-aminobutyric acid receptor subunit epsilon (GABRE) ↗
- Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) ↗
- Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) ↗
- Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) ↗
- GABA receptor alpha-1 subunit
- GABA receptor beta-2 subunit
- GABA receptor alpha-4 subunit
- GABA receptor delta subunit
- GABA receptor alpha-5 subunit
- GABA receptor alpha-6 subunit
- GABA receptor beta-3 subunit
- GABA receptor alpha-3 subunit
- GABA receptor alpha-2 subunit
- GABA-A receptor; GABA-A site (alpha1/beta2 interface)
- GABA-A receptor; alpha-3/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-3/gamma-2
- GABA-A receptor; alpha-5/beta-3/gamma-2
- GABA-A receptor; alpha-2/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-2/gamma-2
- GABA-A receptor; alpha-6/beta-3/gamma-2
- GABA-A receptor; benzodiazepine site
- GABA-A receptor; agonist GABA site
- GABA A receptor alpha-2/beta-2/gamma-2
- GABA A receptor alpha-3/beta-2/gamma-2
- GABA A receptor alpha-6/beta-2/gamma-2
- GABA A receptor alpha-1/beta-1/gamma-2
- GABA A receptor alpha-4/beta-3/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta
- Gamma-aminobutyric acid receptor subunit alpha-1/ beta-1
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3/theta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-6/beta-3
- GABA-A receptor alpha-1/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/beta-2/delta
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/delta
- Gamma-aminobutyric acid receptor subunit beta-1/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-1/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-1/delta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2/gamma-2
- GABA receptor beta-1 subunit
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2
Approval history
- approvedOct 16, 1981
Chemistry & pharmacology
SMILES
CC1=NN=C2CN=C(C3=CC=CC=C3)C4=CC(Cl)=CC=C4N12- Mol. weight
- 308.765 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAlprazolam ↗
- NCATSYU55MQ3IZY ↗
- ChEMBLCHEMBL661 ↗
- WikipediaBenzodiazepine ↗
Also known as
- 8-chloro-1-methyl-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
- 8-chloro-1-methyl-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
- al-704
- alprazolam
- alprazolam
- alprazolam
- alprazolam
- alprazolam
- alprazolam
- alprazolam
- alprazolam
- alprazolam
- alprozolam
- alzolam
- benzodiacepine
- benzodiazepine
- benzodiazepine
- benzodiazepine
- jnj-54257099
- niravam
- niravam
- niravam
- u-31889
- u-31889
- xanax
- xanax
- xanax
- xanax
- xanax
- xanax
- xanax
- xanax
- xanax xr
- xanax xr
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07275710 | N/A | Feb 1, 2026 | Government of Pakistan |
| NCT07154147 | Phase 4 | Aug 12, 2025 | University of California, San Francisco |
| NCT07020988 | Phase 1 | Jun 12, 2025 | UCB |
| NCT06757140 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2025 | National Institute on Drug Abuse (NIDA), University of Kentucky |
| NCT05626439 | Phase 1 | Dec 7, 2022 | UCB |
| NCT05602818 | Phase 1 | Nov 15, 2022 | Takeda |
| NCT05076617 | Phase 3 | Dec 31, 2021 | UCB |
| NCT05077904 | Phase 3 | Dec 31, 2021 | UCB |
| NCT05006079 | Phase 2 | Oct 31, 2021 | Henry Ford Health System, Wayne State University |
| NCT06097676 | Phase 4 | Sep 28, 2021 | Azurity Pharmaceuticals |
| NCT04970342 | Phase 1 | Jul 16, 2021 | Acclaro Research Solutions, Inc., Cognitive Research Corporation, NHTSA, University of Iowa |
| NCT04857307 | Phase 1 | Apr 28, 2021 | UCB |
| NCT04802746 | Phase 1 | Mar 9, 2021 | UCB |
| NCT04782388 | Phase 1 | Mar 4, 2021 | UCB |
| NCT04715269 | Phase 1/Phase 2 (Phase 2) | Dec 25, 2020 | Sheikh Zayed Medical College, University of Veterinary and Animal Sciences, Lahore |
| NCT04658732 | Phase 1 | Dec 1, 2020 | Cairo University |
| NCT04592536 | Phase 1 | Oct 6, 2020 | Cerevel Therapeutics, LLC, Leiden University |
| NCT04184141 | Phase 4 | Dec 1, 2019 | Istanbul Medeniyet University |
| NCT03928236 | N/A | Sep 30, 2019 | McMaster University, University of Manitoba |
| NCT03948243 | Phase 1 | Apr 1, 2019 | Oregon State University, University of Illinois at Chicago |
Organizations
Research & Development (92)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 18 | 17 | 3 | 2003 |
| UCB | For profit | 7 | 7 | 2 | 2021 |
| PRACS | For profit | 6 | 0 | 1 | 2005 |
| GlaxoSmithKline | For profit | 5 | 5 | 1 | 2006 |
| National Institute on Drug Abuse (NIDA) | Government | 5 | 2 | 3 | 1997 |
| Actavis | For profit | 4 | 4 | 1 | 2005 |
| Alexza Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2005 |
| Isfahan University | Academic/Hospital | 3 | 3 | 2 | 2011 |
| Kendle International Inc. | For profit | 3 | 0 | 1 | 2004 |
| Mylan | For profit | 3 | 3 | 1 | 2004 |
| Cognitive Research Corporation | For profit | 2 | 0 | 1 | 2017 |
| Engage Therapeutics Inc. | For profit | 2 | 2 | 2 | 2018 |
| Hoosier Cancer Research Network | Academic/Hospital | 2 | 2 | 2 | 2004 |
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 2 | 2010 |
| Mclean Hospital | Academic/Hospital | 2 | 2 | 2 | 2011 |
| McMaster University | Academic/Hospital | 2 | 2 | 2 | 2017 |
| National Institute of Mental Health (NIMH) | Government | 2 | 0 | 2 | 2006 |
| Orion Corporation | For profit | 2 | 2 | 1 | 2009 |
| PharmaKinetics Laboratories Inc. | For profit | 2 | 0 | 1 | 1991 |
| Sandoz | For profit | 2 | 2 | 1 | 1991 |
Marketing (42)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Actavis | For profit | MKTG | Oct 31, 1993 |
| Actavis | For profit | SYN | May 13, 2010 |
| Amneal Pharmaceuticals | For profit | MKTG | May 30, 2008 |
| Anchen Pharmaceuticals, Inc | For profit | MKTG | Sep 29, 2011 |
| Ani Pharmaceuticals | For profit | MKTG | Feb 16, 1994 |
| Ani Pharmaceuticals | For profit | SYN | Feb 16, 1994 |
| Apax Partners | For profit | MKTG | Oct 15, 2007 |
| Apotex | For profit | MKTG | Jan 19, 2007 |
| Aurobindo Pharma | For profit | MKTG | Jun 7, 2011 |
| Aurobindo Pharma | For profit | SYN | Jun 7, 2011 |
| Boehringer Ingelheim | For profit | MKTG | May 27, 1993 |
| DAVA Pharmaceuticals | For profit | MKTG | Oct 19, 1993 |
| Esteve Labs | For profit | MKTG | Jul 9, 2018 |
| Esteve Labs | For profit | SYN | Jul 9, 2018 |
| Heritage Pharma | For profit | MKTG | Oct 17, 2008 |
| Hikma | For profit | MKTG | Oct 31, 1993 |
| Hikma | For profit | SYN | Oct 31, 1993 |
| Impax Laboratories | For profit | MKTG | May 24, 2007 |
| Impax Laboratories | For profit | SYN | Jan 31, 2007 |
| Mylan | For profit | MKTG | Jan 27, 1994 |
| Mylan | For profit | SYN | Oct 19, 1993 |
| Natco Pharma | For profit | SYN | Apr 15, 2015 |
| Natco Pharma | For profit | MKTG | Apr 15, 2015 |
| Novartis | For profit | MKTG | Mar 25, 1998 |
| Novitium Pharma | For profit | MKTG | Oct 19, 1993 |
| Oxford Pharmaceuticals | For profit | MKTG | Sep 25, 2008 |
| Par Pharmaceuticals | For profit | MKTG | Jan 9, 2009 |
| Pharmacia | For profit | NDA2 | Jan 17, 2003 |
| Pharmacia & Upjohn | For profit | NDA2 | Oct 16, 1981 |
| Roxane Laboratories | For profit | MKTG | May 27, 1993 |
| Sandoz | For profit | MKTG | Dec 29, 1995 |
| Sandoz | For profit | SYN | Jun 30, 2006 |
| Strides Pharma Science | For profit | MKTG | Sep 17, 2010 |
| Sun Pharmaceuticals | For profit | MKTG | Jun 17, 2010 |
| Sun Pharmaceuticals | For profit | SYN | Jun 17, 2010 |
| Teva | For profit | MKTG | Jul 29, 1994 |
| UCB | For profit | NDA2 | Jan 19, 2005 |
| Upjohn | For profit | MKTG | Oct 16, 1981 |
| Upjohn | For profit | NDA | Oct 16, 1981 |
| Vintage | For profit | MKTG | Oct 15, 2007 |
| Watson Pharmaceuticals | For profit | MKTG | Aug 31, 1995 |
| West-Ward Pharmaceutical | For profit | MKTG | Oct 31, 1993 |